Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer
Authors:
- Ate van der GaastAGAte van der Gaast
- Luca IncrocciLILuca Incrocci
- Herman van DekkenHDHerman van Dekken
- John J. HermansJHJohn J. Hermans
- Johannes JeekelJJJohannes Jeekel
- Wim C. J. HopWHWim C. J. Hop
- Geert KazemierGKGeert Kazemier
- Casper H. J. van EijckCECasper H. J. van Eijck
- 1 December 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 248 (6) , 1031-1041
Abstract
Success of surgical treatment for pancreatic and periampullary cancer is often limited due to locoregional recurrence and/or the development of distant metastases. The survival benefit of celiac axis infusion (CAI) and radiotherapy (RT) versus observation after resection of pancreatic or periampullary cancer was investigated. In a randomized controlled trial, 120 consecutive patients with histopathologically proven pancreatic or periampullary cancer received either adjuvant treatment consisting of intra-arterial mitoxantrone, 5-FU, leucovorin, and cisplatinum in combination with 30 x 1.8 Gy radiotherapy (group A) or no adjuvant treatment (group B). Groups were stratified for tumor type (pancreatic vs. periampullary tumors). After surgery, 120 patients were randomized (59 patients in the treatment group, 61 in the observation group). The median follow-up was 17 months. No significant overall survival benefit was seen (median, 19 vs. 18 months resp.). Progressive disease was seen in 86 patients: in 37 patients in the CAI/RT group, and in 49 patients in the observation group (log-rank P < 0.02). Subgroup analysis showed significantly less liver metastases after adjuvant treatment in periampullary tumors (log-rank P < 0.03) without effect on local recurrence. Nonetheless, there was no significant effect on overall survival in these patients (log-rank P = 0.15). In patients with pancreatic cancer, CAI/RT had no significant effect on local recurrence (log-rank P = 0.12) neither on the development of liver metastases (log-rank P = 0.76) and consequently, no effect on overall survival. This adjuvant treatment schedule results in a prolonged time to progression. For periampullary tumors, CAI/RT induced a significant reduction in the development of liver metastases, with a possible effect on overall survival. Especially in these tumors, CAI/RT might prove beneficial in larger groups and further research is warranted.Keywords
This publication has 29 references indexed in Scilit:
- Adjuvant Therapy of Pancreatic CancerThe Cancer Journal, 2007
- Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerJAMA, 2007
- The case for routine use of adjuvant therapy in pancreatic cancerJournal of Surgical Oncology, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Influence of Surgical Resection and Post-Operative Complications on Survival following Adjuvant Treatment for Pancreatic Cancer in the ESPAC-1 Randomized Controlled TrialDigestive Surgery, 2005
- Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trialThe Lancet, 2001
- Current Management of Pancreatic CarcinomaAnnals of Surgery, 1995
- Long-Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving?Annals of Surgery, 1995
- Results of resection for cancer of the exocrine pancreas: A study from the French Association of SurgeryBritish Journal of Surgery, 1994
- Carcinoma of the pancreas and periampullary region: Palliation versus cureBritish Journal of Surgery, 1993